# **Special Issue**

# Novel Strategy and Technologies in Local and Locoregional Treatment for Lung Cancer

## Message from the Guest Editors

We are pleased to invite you to contribute to our Special Issue which is focused on the current state of the art and possible future innovations in the treatment of local and locoregional lung cancer.

This Special Issue aims to help all readers clarify current standards and the practice-changing studies which are currently ongoing to understand the possible future direction of the treatment of local and locoregional lung cancer.

Articles should focus on novel surgical approaches or describe innovative techniques, report results of trials or studies and outline rare presentations of lung cancer which required tailored treatments.

The manuscripts could focus on treatments of nonsmall cell and small cell lung cancer and lung metastasis.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: oncology, radiotherapy, thoracic surgeons, pathologists, pneumologists, radiologists and interventional pneumologists. We look forward to receiving your contributions.

#### **Guest Editors**

Dr. Francesco Guerrera

Department of Cardio-Thoracic and Vascular Surgery, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

Dr. Pietro Bertoglio

Division of Thoracic Surgery, Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy

### Deadline for manuscript submissions

closed (30 November 2023)



# **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/102414

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





# **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



## **About the Journal**

### Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

